Ultime notizie per OncoSec Medical (OTC:ONCSQ) Azioni

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

ONCOSEC MEDICAL INC NEW by OncoSec Medical Incorporated

OncoSec Medical Inc

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

Guidance

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

<a href="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/" title="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/">https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/</a>

Tech

AAPL

Reported Earlier, Apple's New iPhone Sales In China Rose 20% In First 3 Weeks

EV <a href="https://www.benzinga.com/news/24/10/41223011/rivians-production-guidance-cut-spurred-by-miscommunication-with-atlanta-based-supplier-resulting-in">startup</a> Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) said on Thursday that it will launch its Halloween software update starting Oct. 18, complete with spooky features and car costumes.
What Happened: The company announced the update in a video posted on social media platform X featuring actor David Hasselhoff who starred in the Knight Rider series.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">An iconic duo reunited <a href="https://twitter.com/DavidHasselhoff?ref_src=twsrc%5Etfw">@DavidHasselhoff</a>.⁰ The countdown is on. Our Halloween software update arrives after the clock strikes midnight (local). Spooky features will be available for a limited time. <a href="https://t.co/hdKV0z4WIC">pic.twitter.com/hdKV0z4WIC</a>
&mdash; Rivian (@Rivian) <a href="https://twitter.com/Rivian/status/1846945663860572411?ref_src=twsrc%5Etfw">October 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
One of the car costumes available with the update is inspired by Knight Rider. The costume will alter the Rivian&#8217;s interior display system and the exterior lightbar on Gen 2 R1 vehicles will cascade a red beam to replicate the experience of K.I.T.T, the robotic automobile that featured in the series.
There are also other car costumes available with the update, inspired by iconic and classic vehicles from pop culture, such as one inspired by the time machine in Universal Pictures and Amblin Entertainment's Back to the Future, in addition to a spooky option. 
The haunted Rivian car costume has eight different sound effects and three different color themes to choose from ranging between purple, yellow, red, and green. The interior display screen will feature static and ghosts to increase the spooky feeling when the vehicle is parked with the costume. 
Besides Costumes: Besides costumes, Rivian&#8217;s new update changes pedestrians on the driver display to zombies and bicyclists and motorcyclists into headless horsemen. 
Vehicle owners can also play multiple spooky chirp sounds, including one resembling the owl. 
However, the spooky features will only be available for a limited time until November 4, the company warned. Additionally, <a href="https://www.benzinga.com/news/24/08/40574576/rivian-or-lucid-which-of-the-two-loss-making-ev-startups-is-solving-cash-burn">both the vehicle</a> and the Rivian mobile app must be updated to their latest versions for the features, it added.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX's Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them'</a></li>
</ul>
Photo courtesy: Rivian

RIVN

Trick Or Treat: Rivian Rolls Out Spooky Halloween Update Featuring Car Costumes, Creepy Chirps

China-based U.S.-listed stocks experienced a notable pre-market rally on Friday, driven by China&#8217;s better-than-expected GDP figures for the third quarter.
What Happened: Several major Chinese companies saw significant gains. As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, Alibaba Group Holding Ltd &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) rose by 3.23%, while its rival PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) increased by 5.38%. Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) climbed 4.23%, and JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) was up 5.05%. In the electric vehicle sector, Nio Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) and Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) saw increases of 5.44% and 6.48%, respectively.
China&#8217;s GDP grew by 4.6% year-over-year in the third quarter, surpassing expectations from a Reuters poll, though slightly below the 4.7% growth in the previous quarter. As per CNBC, this marks the slowest growth rate since mid-last year, moving further from Beijing&#8217;s 5% annual target. 
Retail sales in September grew by 3.2% year-on-year, exceeding forecasts, and industrial output rose by 5.4%, also surpassing expectations. However, house prices fell by 5.8% year-over-year in September, a larger decline than the 5.3% drop in August. Meanwhile, the CSI 300 index in Mainland China surged 3.62% to close at 3,925.23, after hitting an intraday high of 5.5%.
See Also: <a href="https://www.benzinga.com/news/24/10/41325447/after-pulling-down-oil-prices-with-weak-demand-china-urges-israel-iran-to-avoid-vicious-circle-of-co?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">After Pulling Down Oil Prices With Weak Demand, China Urges Israel, Iran To Avoid &#8216;Vicious Circle&#8217; Of Conflict</a>
Why It Matters: The recent economic data comes amid China&#8217;s efforts to stave off a potential economic downturn. In late September, China announced a <a href="https://www.benzinga.com/markets/equities/24/10/41182930/china-was-tipping-into-a-japan-style-lost-decade-of-deflation-and-stagnation-before-late-septemb">series of stimulus measures,</a> including a 50 basis-point cut to the mandatory reserve ratio and a reduction in the benchmark policy rate by 0.2 percentage points. The People's Bank of China also reduced rates on existing mortgages and lowered the minimum down payment on second homes. Despite these efforts, investor sentiment remained cautious, as the absence of a<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41316058/chinese-stocks-etfs-struggle-as-multi-trillion-yuan-stimulus-hopes-fall-short-yet-m"> large-scale economic package</a> left traders underwhelmed. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41316396/lululemon-fresh-and-unique-shows-promise-thanks-to-china-opportunity-growth-push-sa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lululemon &#8216;Fresh And Unique,&#8217; Shows Promise Thanks To China Opportunity, Growth Push Say Analysts</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Asia

Global

Pre-Market Outlook

Markets

General

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Why Are Alibaba, Nio, JD.Com And Other US-Listed Chinese Stocks Surging Today?

Another billionaire investor is rooting for Republican presidential candidate Donald Trump&#8217;s victory in the Nov. 5 election and has accordingly positioned his portfolio. The call comes on the heels of former hedge fund manager Stanley Druckenmiller&#8216;s<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41375637/market-very-convinced-of-a-trump-win-says-stanley-druckenmiller-why-billionaire-inv"> similar prediction.</a>
What&#8217;s In Store In Political Arena: &#8220;We believe that the likelihood of a Republican victory in the White House has increased, which would have a positive impact on certain sectors and the market overall,&#8221; said hedge fund Third Point founder and CEO Daniel Loeb said in the firm&#8217;s third-quarter investor letter. 
The hedge fund manager said the &#8220;America First&#8221; tariffs will increase domestic manufacturing, infrastructure spending, and prices of certain materials and commodities. He also said a potential reduction in regulation in the activist antitrust stance of the Biden-Harris administration would unleash productivity and a wave of corporate activity.
&#8220;Accordingly, we have increased certain positions that could benefit from such a scenario via both stock and option purchases and continue to shift our portfolio away from companies that will not,&#8221; the hedge fund manager said. A study of Senate races will likely see Republicans establishing a majority, thus precluding a &#8220;Blue Sweep&#8221; if Kamala Harris wins the race to the White House, according to the hedge-fund manager.
He warned of a &#8220;Blue sweep&#8221; theoretically ushering in crushing taxes, stifling regulations, and a headwind to growth.
See Also:<a href="https://www.benzinga.com/money/cyclical-stocks"> What Are Cyclical Stocks</a>
Economic Outlook: Loeb reassured investors regarding the economy. &#8220;In the economy, we see no evidence of recession, slowing inflation, and a real interest rate that still needs to come down,&#8221; he said.
The hedge fund manager also sees healthy consumer spending, and active levels of individual investing, providing a liquidity backdrop to sustain market levels. The setup is good for event-driven investing, he said, adding that &#8220;the potential for risk arbitrage transactions and corporate activity could usher in a golden age for the strategy.&#8221;
Third Point&#8217;s Q3 Winners &amp; Losers: Third Point Offshore Fund generated a return of 3.9%, taking the annualized net returns to 13.1%. The third-quarter returns of the fund, however, paled before the S&amp;P 500&#8217;s 5.9% gain and the MSCI World Index&#8217;s 6.5% rise.
Loeb noted that the global market gains continued in the third quarter but the rally broadened out in the quarter, with the Magnificent 7 trailing the broader market for the first time since the fourth quarter of 2022. Rate-sensitive stocks and cyclicals outperformed as the market looked ahead to the easing cycle, he added.
The top gainers and decliners of the fund are as follows:
Gainers
<ul>
<li>Privately-held R2 Semiconductor</li>
<li>PG&amp;E Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) Pacific Gas and Electric Company&nbsp;subsidiary</li>
<li>Utility Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)</li>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>)</li>
<li>Lifesciences and diagnostics company Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)</li>
</ul>
Losers:
<ul>
<li>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>)</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
</ul>
Loeb also said his fund initiated a position in Danish freight forwarder DSV. &#8220;We believe DSV can earn more than 100 DKK per share in 2027 and see significant upside for one of Europe's best companies,&#8221; he said.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the performance of the S&amp;P 500 Index, traded up 0.25% to $583.78&nbsp;in premarket trading on Friday, according to<a href="https://benzinga.grsm.io/register174"> Benzinga Pro data.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41374232/amid-nvidias-stratospheric-rally-billionaire-investor-druckenmiller-regrets-cashing-out-of-ai-st">Amid Nvidia&#8217;s Stratospheric Rally, Billionaire Investor Druckenmiller Regrets Cashing Out Of AI Stalwart&#8217;s Stock: &#8216;I&#8217;m Licking My Wounds From A Bad Sale&#8217;</a></li>
</ul>
Image via Flickr

Analyst Color

Economics

AMZN

BBWI

GOOG

GOOGL

MSFT

Hedge Fund Billionaire Daniel Loeb Bets On Trump Win, Singles Out This Recent Buy As Having 'Significant Upside Potential'

<a href="https://www.wsj.com/articles/bausch-health-rejects-bondholders-debt-proposals-explores-sale-of-vision-care-unit-f7832964" title="https://www.wsj.com/articles/bausch-health-rejects-bondholders-debt-proposals-explores-sale-of-vision-care-unit-f7832964">https://www.wsj.com/articles/bausch-health-rejects-bondholders-debt-proposals-explores-sale-of-vision-care-unit-f7832964</a>

Asset Sales

BLCO

The Wall Street Journal Reported Thursday, Bausch Health Rejects Bondholders' Debt Proposals; Explores Sale Of Its Bausch + Lomb Vision Care Subsidiary

Piper Sandler analyst Brent Bracelin maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Overweight and raises the price target from $34 to $45.

KVYO

Piper Sandler Maintains Overweight on Klaviyo, Raises Price Target to $45

Piper Sandler analyst Brent Bracelin maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Overweight and lowers the price target from $485 to $470.

Comments

OncoSec Medical

Notizie

Ultime notizie per OncoSec Medical (OTC:ONCSQ) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO